Bank of New York Mellon Corp Has $1.66 Million Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

Bank of New York Mellon Corp raised its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 24.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 423,209 shares of the company’s stock after acquiring an additional 83,025 shares during the period. Bank of New York Mellon Corp owned approximately 0.40% of MaxCyte worth $1,659,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in MaxCyte in the 1st quarter valued at $28,000. PNC Financial Services Group Inc. acquired a new position in MaxCyte in the 4th quarter valued at $29,000. Victory Capital Management Inc. raised its holdings in MaxCyte by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 12,316 shares of the company’s stock valued at $58,000 after acquiring an additional 2,306 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in MaxCyte by 65.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company’s stock valued at $83,000 after acquiring an additional 7,898 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of MaxCyte by 20.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock worth $106,000 after buying an additional 4,320 shares in the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at MaxCyte

In other news, Director Stanley C. Erck sold 29,767 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total transaction of $118,174.99. Following the completion of the transaction, the director now owns 269,118 shares of the company’s stock, valued at approximately $1,068,398.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other MaxCyte news, Director Stanley C. Erck sold 29,767 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total value of $118,174.99. Following the completion of the transaction, the director now owns 269,118 shares of the company’s stock, valued at approximately $1,068,398.46. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Thomas M. Ross sold 15,476 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $4.54, for a total value of $70,261.04. Following the completion of the transaction, the executive vice president now directly owns 25,000 shares of the company’s stock, valued at approximately $113,500. The disclosure for this sale can be found here. In the last quarter, insiders sold 74,774 shares of company stock valued at $309,956. Corporate insiders own 3.00% of the company’s stock.

MaxCyte Stock Performance

MaxCyte stock opened at $4.06 on Thursday. MaxCyte, Inc. has a 52 week low of $2.45 and a 52 week high of $5.55. The stock has a market capitalization of $425.59 million, a P/E ratio of -11.60 and a beta of 1.40. The stock has a fifty day moving average of $4.30 and a 200-day moving average of $4.27.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. The company had revenue of $10.43 million during the quarter, compared to analysts’ expectations of $8.20 million. During the same quarter in the previous year, the firm earned ($0.10) EPS. On average, research analysts forecast that MaxCyte, Inc. will post -0.44 earnings per share for the current year.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.